A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2029-08-03
Target enrollment:
Participant gender:
Summary
This is a FIH, multicenter, open-label Phase I study to investigate the safety, tolerability,
preliminary antitumor activity, as well as PK and pharmacodynamics of XL309 (previously
ISM3091) administered alone or in combination with olaparib in subjects with advanced solid
tumors.